Moderna, Inc. (NASDAQ:MRNA) shares are trending on Wednesday. The company received a $176 million award from the Rapid Response Partnership Vehicle to boost Influenza vaccine development.
What To Know: On Tuesday, the company announced this award which will aid in the development of an mRNA-based vaccine against the H5 influenza virus.
“mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna.
Last year the company started a Phase 1/2 study of possible vaccine candidates against the H5 and H7 influenza viruses, results are expected sometime in 2024.
What Else: Moderna’s RSV vaccine, on June 28, received positive opinion from the Committee for ...